Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?

References

• Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020;3:1–4.
   Google Scholar
• Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127–20.
   PubMed Web of Science ®Google Scholar
• Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA. 2005;102:797–801.
   PubMed Web of Science ®Google Scholar
• He Y, Li J, Li W, et al. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol. 2006;176(10):6085–6092.
   PubMed Web of Science ®Google Scholar
• Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV–a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236.
   PubMed Web of Science ®Google Scholar
• Christensen D, Mortensen R, Rosenkrands I, et al. Vaccine-induced Th17 cell are established as resident memory cells in the lung and promote local IgA responses. Mucosal Immunol. 2017;10(1):260–270.
   PubMed Web of Science ®Google Scholar
• Riccomi A, Piccaro G, Christensen D, et al. Parenteral vaccination with a tuberculosis subunit vaccine in presence of retinoic acid provides early but transient protection to M. Tuberculosis infection. Front Immunol. 2019;10:934.
   PubMed Web of Science ®Google Scholar
• Allie SR, Bradley JE, Mudunuru U, et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat Immunol. 2019;20(1):97–108.
   PubMed Web of Science ®Google Scholar
• COVID-19 Vaccine Frontrunners. [cited 2020 Apr 11]. Available from https://www.the-scientist.com/news-opinion/covid-19-vaccine-frontrunners-67382
   Google Scholar
• Bharat Biotech. [cited 2020 Apr 11]. Available from https://www.bharatbiotech.com/
   Google Scholar
• Wang N, Shang J, Jiang S, et al. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;11:298.
   PubMed Web of Science ®Google Scholar
• Shim BS, Stadler K, Nguyen HH, et al., Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. Virol J. 9(1): 215. 2012.
   PubMedGoogle Scholar
• Shim BS, Park SM, Quan JS, et al., Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses. BMC Immunol. 11(1): 65. 2010.
   PubMedGoogle Scholar
• Huang X, Lu B, Yu W, et al., A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One. 4(1): e4180. 2009.
   PubMed Web of Science ®Google Scholar
• Du L, Zhao G, Lin Y, et al., Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol. 180(2): 948–956. 2008.
   PubMed Web of Science ®Google Scholar
• Hu MC, Jones T, Kenney RT, et al. Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice. Vaccine. 2007;25(35):6334–6340.
   PubMedGoogle Scholar
• Zhao J, Zhao J, Mangalam AK, et al. Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity. 2016;44(6):1379–1391.
   PubMed Web of Science ®Google Scholar
• Li E, Chi H, Huang P, et al. A novel bacterium-like particle vaccine displaying the MERS-CoV receptor-binding domain induces specific mucosal and systemic immune responses in mice. Viruses. 2019;11(9):799.
   PubMed Web of Science ®Google Scholar
• Munster VJ, Wells D, Lambe T, et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. NPJ Vaccines. 2017;2(1):1–4.
   PubMedGoogle Scholar
• Haagmans BL, van den Brand JM, Raj VS, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351(6268):77–81.
   PubMed Web of Science ®Google Scholar
• Ma C, Li Y, Wang L, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32(18):2100–2108.
   PubMed Web of Science ®Google Scholar
• Raghuwanshi D, Mishra V, Das D, et al. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein. Mol Pharm. 2012;9(4):946–956.
   PubMed Web of Science ®Google Scholar
• Gai WW, Zhang Y, Zhou DH, et al. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV. Virol Sin. 2011;26(2):81–94.
   PubMedGoogle Scholar
• Lu B, Huang Y, Huang L, et al. Effect of mucosal and systemic immunization with virus‐like particles of severe acute respiratory syndrome coronavirus in mice. Immunology. 2010;130(2):254–261.
   PubMed Web of Science ®Google Scholar
• Schulze K, Staib C, Schätzl HM, et al. A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. Vaccine. 2008;26(51):6678–6684.
   PubMed Web of Science ®Google Scholar
• Luo F, Feng Y, Liu M, et al. Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination. Clin Vaccine Immunol. 2007;14(8):990–997.
   PubMedGoogle Scholar
• Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;pii:S0016-5085(20)30282–1.
   Google Scholar
• Marasini N, Kaminskas LM. Subunit-based mucosal vaccine deliveryg systems for pulmonary delivery-Are they feasible? Drug Dev Ind Pharm. 2019;45(6):882–894.
   PubMed Web of Science ®Google Scholar
• Holt PG, Strickland DH, Wikström ME, et al. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol. 2008;8(2):142–152.
   PubMed Web of Science ®Google Scholar
• Hellfritzsch M, Scherließ R. Mucosal vaccination via the respiratory tract. Pharmaceutics. 2019;11(8):375.
   PubMed Web of Science ®Google Scholar
• Ma Y. Recent advances in nontoxic Escherichia coli heat-labile toxin and its derivative adjuvants. Expert Rev Vaccines. 2016;15(11):1361–1371.
   PubMed Web of Science ®Google Scholar
• Kim SH, Seo KW, Kim J, et al. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J Immunol. 2010;185(10):5787–5795.
   PubMed Web of Science ®Google Scholar
• Rosales-Mendoza S, Angulo C, Meza B. Food-grade organisms as vaccine biofactories and oral delivery vehicles. Trends Biotechnol. 2016;34(2):124–136.
   PubMed Web of Science ®Google Scholar
• Serradell MC, Rupil LL, Martino RA, et al. Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins. Nat Commun. 2019;10(1):361.
   PubMed Web of Science ®Google Scholar
• Tomar J, Born PA, Frijlink HW, et al., Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination. Expert Rev Vaccines. 15(11): 431–1447. 2016.
   Web of Science ®Google Scholar
• Eickhoff CS, Blazevic A, Killoran EA, et al. Induction of mycobacterial protective immunity by sublingual BCG vaccination. Vaccine. 2019;37(36):5364–5370.
   PubMed Web of Science ®Google Scholar
• Gallorini S, Taccone M, Bonci A, et al. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. Vaccine. 2014;32(20):2382–2388.
   PubMed Web of Science ®Google Scholar
• Samuelson DR, Welsh DA, Shellito JE. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015;6:1085.
   PubMed Web of Science ®Google Scholar